/
Other
Interleukin
4
Pipeline Programs↗
5
Active Trials↗
7
Companies Involved↗
Interleukin is an early-stage landscape with 4 programs across 7 companies. The most active players are Jecho Biopharmaceuticals Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
67%
Small molecule
2 of 3 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 100% of 4 pipeline programs.
Analysis
Trial Status
62
clinical trials
Completed46 · 74%
Terminated6 · 10%
Unknown status4 · 6%
Recruiting3 · 5%
Not yet recruiting1 · 2%
Withdrawn1 · 2%
Other1 · 2%
Clinical Trials
Trial Activity
62 trials
Subcutaneously Administered Interleukin-2 Therapy in HIV-Infected Patients
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001357·80 enrolled
A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD
Completed·—·Phase 2·NCT02340676·25 enrolled
Efficacy of Using Interleukin-2 in Antiretroviral Naïve HIV Patients (ANRS119)
Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00120185·130 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)